Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 9/20 | 0.61 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038573 | 0.93 | NPY1R (0.63) | NPY1RCRHR1ALDH1A1HPGDUSP2 | |
| SCHEMBL5728776 | 0.75 | NPY1R (0.85) | NPY1RCRHR1ALDH1A1HPGDUSP2 | |
| Hydrochloric Acid SCHEMBL5729611 | 0.74 | NPY1R (0.81) | NPY1RCRHR1ALDH1A1HPGDUSP2 | |
| SCHEMBL5729134 | 0.74 | NPY1R (0.85) | NPY1RCRHR1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5728933 | 0.73 | NPY1R (0.83) | NPY1RCRHR1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5729567 | 0.71 | NPY1R (0.79) | NPY1RCRHR1ALDH1A1HPGDUSP2 | |
| SCHEMBL5729215 | 0.71 | NPY1R (1.00) | NPY1RALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL5729654 | 0.71 | NPY1R (0.78) | NPY1RCRHR1ALDH1A1HPGDUSP2 | |
| SCHEMBL7044284 | 0.71 | NPY1R (0.78) | NPY1RCRHR1ALDH1A1HPGDUSP2 | |
| SCHEMBL5729799 | 0.70 | NPY1R (0.98) | NPY1RALDH1A1HPGDUSP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218381-B1 | AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES | NEUROGEN CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6476038-B1 | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION | 2002-11-05 | — | — | US | disclosed |
| EP-1218381-A2 | AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| WO-2001023388-A2 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | NPY1R 198/4885CRHR1 150/4885ALDH1A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.